Bio-Gene Technology

Bio-Gene Technology Retained Earnings

The Retained Earnings of Bio-Gene Technology (BGT.AX) as of Oct 21, 2026 is -24.20 M AUD. In the previous year, Retained Earnings was -22.03 M AUD — a change of 9.85% (lower).

Retained Earnings

-24.20 MAUD

YoY

9.85%

Last updated:

Retained Earnings of Bio-Gene Technology is 2026 -24.20 M AUD. Retained Earnings of Bio-Gene Technology was 2025 -22.03 M AUD. It decreases by 9.85% lower compared to the previous year.

The Bio-Gene Technology Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2019
-7.55 M AUD
Jan 1, 2020
-9.48 M AUD
Jan 1, 2021
-11.68 M AUD
Jan 1, 2022
-14.50 M AUD
Jan 1, 2023
-17.43 M AUD
Jan 1, 2024
-19.64 M AUD
Jan 1, 2025
-22.03 M AUD
Jan 1, 2026
-24.20 M AUD
The Bio-Gene Technology Retained Earnings history
YEARRetained EarningsYoY
-24.20 MAUD+9.85%
-22.03 MAUD+12.17%
-19.64 MAUD+12.67%
-17.43 MAUD+20.23%
-14.50 MAUD+24.14%
-11.68 MAUD+23.15%
-9.48 MAUD+25.60%
-7.55 MAUD+37.41%
-5.50 MAUD+85.62%
-2.96 MAUD+84.21%
-1.61 MAUD+44.19%
-1.11 MAUD+14.27%
-975,378.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio-Gene Technology Stock analysis

What does Bio-Gene Technology do? Bio-Gene Technology Ltd develops and commercializes insecticides using beta-triketone platform technology. The company's lead products are Flavocide, a chemically synthesized insecticide based on flavesone, and Qcide, a natural oil product containing tasmanone extracted from Gympie Messmate leaves via steam distillation. These products address insecticide resistance and toxicity issues in crop protection, storage, public health, animal health, and consumer applications. Insecticide manufacturers purchase the company's platform technology and products for commercialization across multiple sectors. The firm's beta-triketone platform provides multiple solutions for insecticide manufacturers seeking to develop novel pest control products. Flavocide and Qcide represent the company's primary commercial offerings, with Flavocide targeting synthetic insecticide markets and Qcide focusing on natural oil-based solutions. The company's technology enables the development of targeted insect control solutions for various applications including agricultural crop protection and public health management. Bio-Gene Technology Ltd. aims to develop a portfolio of targeted insect control solutions for insecticide manufacturers. The company's platform technology allows manufacturers to create new products addressing resistance and toxicity challenges. Through its two lead products, the company provides both synthetic and natural options for the insecticide market, targeting manufacturers who seek innovative solutions for pest management across different industry segments. Bio-Gene Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Gene Technology stock

Retained Earnings of Bio-Gene Technology is -24.20 M AUD in 2026.

Retained Earnings of Bio-Gene Technology changed from -22.03 M AUD to -24.20 M AUD, representing a 9.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Bio-Gene Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bio-Gene Technology

All Key Metrics — Bio-Gene Technology